Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Elicio Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$9.95
Massimo di 52 settimane	US$14.93
Minimo di 52 settimane	US$5.80
Beta	1.45
Variazione di 1 mese	-14.88%
Variazione a 3 mesi	0%
Variazione di 1 anno	75.80%
Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-45.16%

Notizie e aggiornamenti recenti

Aggiornamento della narrazione • May 21

Favorable Auction Dynamics

While Merck and Amgen are the frontrunners for a KRAS-driven partnership, Elicio’s AMP platform is particularly attractive to a broader subset of "Big Pharma" companies that are currently facing a specific strategic gap: the inability of their existing portfolios to penetrate "cold" tumors like pancreatic (PDAC) and colorectal (CRC) cancers. It is most probable that big pharma is conducting due diligence into RVMD and ELTX in parallel and evaluating outcomes and potential synergies with their existing portfolios.

Aggiornamento della narrazione • May 05

Valuation: 15x upside potential

Determining the valuation for Elicio Therapeutics (ELTX) requires balancing the high-cost nature of specialized immunotherapy with the massive patient populations affected by KRAS mutations. Based on current oncology benchmarks and the clinical profile of the AMP-7P vaccine, here is the projected economic outlook.

Aggiornamento della narrazione • Apr 29

Study on track for success

As of April 28, 2026, based on the enrollment completion of the AMPLIFY-7P Phase 2 study in November 2024, approximately 40% to 45% of the MRD-negative cohort should have progressed by now if there were no treatment effect. This calculation is based on the clinical parameters and natural history data provided in the sources: 1.

Recent updates

Aggiornamento della narrazione • May 21

Favorable Auction Dynamics

Aggiornamento della narrazione • May 05

Valuation: 15x upside potential

Aggiornamento della narrazione • Apr 29

Study on track for success

Aggiornamento della narrazione • Feb 21

10 mg adjuvant = 100% mKRAS specific T-cell response rate

The 10 mg dose of Amph-CpG-7909 improves vaccine efficacy by providing an optimized level of Toll-like receptor 9 (TLR-9) stimulation that is precisely targeted to the lymph nodes, resulting in a 100% T cell response rate and significantly enhanced anti-tumor activity compared to lower doses. The specific mechanisms by which this dose and formulation improve efficacy include: 1.

Articolo di analisi • Feb 10

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Aggiornamento della narrazione • Jan 18

80-90% prob of success

Assuming a conservative 16-month median Disease-Free Survival (DFS) for the observation group—consistent with a nationwide, unselected (MRD-agnostic) surgical PDAC population—the probability that the AMPLIFY-7P Phase 2 study will show a statistically significant improvement in the treatment arm is estimated to be 80–90%. While the 16-month baseline represents a significantly more durable control group than the 5.0–6.4 month median seen in MRD-positive patients, the following factors derived from the sources support this high estimate: 1.

Seeking Alpha • Nov 07

Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent

Summary ELTX is continuing its work on a KRAS vaccine in PDAC, with a phase 2 trial set to read out any day now. Earlier signals of efficacy of their phase 2 trial have shown biological correlation that suggests activity, but we still need to see outcomes of treatment. The company is heavily reliant on a positive read out in order to raise funds for further development. The potential upside here outweighs the admittedly huge downside risk, though. Read the full article on Seeking Alpha

Articolo di analisi • Aug 30

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Rendimenti per gli azionisti

	ELTX	US Biotechs	US Mercato
7D	4.0%	3.1%	1.2%
1Y	75.8%	34.6%	28.7%

Ritorno vs Industria: ELTX ha superato il US Biotechs che ha restituito 34.6 % nell'ultimo anno.

Rendimento vs Mercato: ELTX ha superato il mercato US che ha restituito 28.7 % nell'ultimo anno.

Volatilità dei prezzi

Is ELTX's price volatile compared to industry and market?
ELTX volatility
ELTX Average Weekly Movement	12.8%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di ELTX è stato volatile rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 13% ) di ELTX è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	33	Bob Connelly	elicio.com

Elicio Therapeutics, Inc. è una società di biotecnologie in fase clinica che sviluppa immunoterapie per il trattamento del cancro. Il suo candidato principale, ELI-002, è un vaccino peptidico anfifilico (AMP) multivalente mirato ai linfonodi, in fase di sperimentazione clinica di Fase II per sette mutazioni del driver dell'oncogene virale del sarcoma del ratto Kirsten. L'azienda sviluppa anche ELI-007, un trattamento peptidico AMP multivariato mirato ai linfonodi per i tumori guidati dall'oncogene virale mutante b-raf del sarcoma murino B1-(BRAF), ed ELI-008, un vaccino peptidico AMP multivariato mirato ai linfonodi, in fase di studio preclinico per il trattamento dei tumori mutati della proteina tumorale p53.

Elicio Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Elicio Therapeutics con la sua capitalizzazione di mercato?
ELTX statistiche fondamentali
Capitalizzazione di mercato	US$183.04m
Utili (TTM)	-US$40.18m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-4.6x

Rapporto P/E

ELTX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ELTX Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$40.19m
Utili	-US$40.18m

Ultimi utili riportati

Mar 31, 2026

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.18
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	-659.4%

Come si è comportato ELTX nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/05/25 04:37
Prezzo dell'azione a fine giornata	2026/05/22 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Elicio Therapeutics, Inc. è coperta da 3 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Soumit Roy	JonesTrading Institutional Services, LLC
Boris Peaker	JonesTrading Institutional Services, LLC
Aydin Huseynov	Ladenburg Thalmann & Company

Elicio Therapeutics (ELTX) Panoramica del titolo

Analisi del rischio

Top Community Narratives

Very Bullish

Top Community Narratives

Very Bullish

Concorrenti di Elicio Therapeutics, Inc.

Acumen Pharmaceuticals

Precision BioSciences

Immunic

Tiziana Life Sciences

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Favorable Auction Dynamics

New major risk - Financial position

Valuation: 15x upside potential

Study on track for success

Elicio Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

New minor risk - Shareholder dilution

Recent updates

Favorable Auction Dynamics

New major risk - Financial position

Valuation: 15x upside potential

Study on track for success

Elicio Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

New minor risk - Share price stability

10 mg adjuvant = 100% mKRAS specific T-cell response rate

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?

80-90% prob of success

Elicio Therapeutics, Inc. Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIF-7P Trial

Elicio Therapeutics, Inc. Appoints Marc J. Wolfgang, M.S. as Chief Technology Officer

Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent

Elicio Therapeutics, Inc. Announces Additional Immunogenicity Data from the Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P

Elicio Therapeutics, Inc. to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

Elicio Therapeutics, Inc. Reports Robust T Cell Responses Across Diverse HLA Background in Ongoing Phase 2 AMPLIFY-7P Trial

Elicio Therapeutics, Inc. Announces Investigator-Initiated Phase 1 Trial to Be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt Sensibly?

Elicio Therapeutics, Inc. Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-Up Data in Nature Medicine for Minimal Residual Disease Positive, Adjuvant-Stage Patients

New major risk - Revenue and earnings growth

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from Russell 3000E Growth Index

Elicio Therapeutics, Inc. announced that it expects to receive $10 million in funding

New major risk - Financial position

Elicio Therapeutics, Inc., Annual General Meeting, May 19, 2025

Elicio Therapeutics Appoints Preetam Shah as Chief Strategy and Financial Officer

Director exercised options to buy US$28m worth of stock.

Elicio Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000003 million.

New minor risk - Share price stability

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

New major risk - Financial position

Elicio Therapeutics, Inc. Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Elicio Therapeutics, Inc. Appoints Robert Connelly as Principal Accounting Officer and Principal Financial Officer

Price target decreased by 9.1% to US$10.00

Less than half of directors are independent

Elicio Therapeutics, Inc., Annual General Meeting, Nov 07, 2024

Elicio Therapeutics, Inc. announced that it expects to receive $20 million in funding from Gkcc, LLC

Elicio Therapeutics, Inc. has filed a Follow-on Equity Offering.

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting

New major risk - Financial position

Elicio Therapeutics, Inc. announced that it has received $5.999999 million in funding from Gkcc, LLC

Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Elicio Therapeutics, Inc. Publishes Updated Preliminary Phase 1 Data from AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Elicio Therapeutics, Inc. announced that it has received $7.04753 million in funding from Gkcc, Llc

Elicio Therapeutics, Inc. Announces Resignation of Annette Matthies as Chief Business Officer

Elicio Therapeutics, Inc. Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 At AACR Special Conference: Pancreatic Cancer

Less than half of directors are independent

Elicio Therapeutics, Inc. Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer

Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. (NasdaqGS:ANGN) from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.

Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. (NasdaqGS:ANGN) in a reverse merger transaction.

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Elicio Therapeutics, Inc. Riepilogo dei fondamenti

Utili e ricavi

Analisi aziendale e situazione dei dati finanziari